IL299744A - Antibodies to CD-3 for the treatment of the corona virus - Google Patents
Antibodies to CD-3 for the treatment of the corona virusInfo
- Publication number
- IL299744A IL299744A IL299744A IL29974423A IL299744A IL 299744 A IL299744 A IL 299744A IL 299744 A IL299744 A IL 299744A IL 29974423 A IL29974423 A IL 29974423A IL 299744 A IL299744 A IL 299744A
- Authority
- IL
- Israel
- Prior art keywords
- coronavirus
- antibodies
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058978P | 2020-07-30 | 2020-07-30 | |
| PCT/EP2021/071491 WO2022023566A2 (en) | 2020-07-30 | 2021-07-30 | Cd-3 antibodies for the treatment of coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299744A true IL299744A (en) | 2023-03-01 |
Family
ID=77543470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299744A IL299744A (en) | 2020-07-30 | 2021-07-30 | Antibodies to CD-3 for the treatment of the corona virus |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230227555A1 (https=) |
| EP (1) | EP4188440A2 (https=) |
| JP (1) | JP2023535792A (https=) |
| CN (1) | CN116406274B (https=) |
| AU (1) | AU2021316723A1 (https=) |
| CA (1) | CA3185105A1 (https=) |
| IL (1) | IL299744A (https=) |
| WO (1) | WO2022023566A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| WO2023218100A1 (en) * | 2022-05-13 | 2023-11-16 | Tiziana Life Sciences Plc | Nasal formulations of foralumab |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654210A (en) | 1979-04-26 | 1987-03-31 | Ortho Pharmaceutical Corporation | Methods and compositions using complement fixing monoclonal antibody to human T cells |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| WO1991006319A1 (en) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US7883703B2 (en) * | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| MX2008014710A (es) * | 2006-05-19 | 2009-02-12 | Amgen Inc | Anticuerpos para coronavirus del sars. |
| AU2014319921A1 (en) * | 2013-09-11 | 2016-03-17 | Compugen Ltd. | Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis |
| CN116617387A (zh) * | 2016-08-29 | 2023-08-22 | 迪赞纳生命科学公开有限公司 | 抗cd3抗体制剂 |
| EP3634478A4 (en) * | 2017-06-06 | 2021-03-24 | The Brigham and Women's Hospital, Inc. | METHOD OF SUPPRESSION OF MICROGLIA ACTIVATION |
| IL296276A (en) * | 2020-03-10 | 2022-11-01 | Tiziana Life Sciences Plc | Compositions of il-6/il-6r antibodies and methods of use thereof |
-
2021
- 2021-07-30 CN CN202180059947.8A patent/CN116406274B/zh active Active
- 2021-07-30 CA CA3185105A patent/CA3185105A1/en active Pending
- 2021-07-30 JP JP2023505756A patent/JP2023535792A/ja active Pending
- 2021-07-30 IL IL299744A patent/IL299744A/en unknown
- 2021-07-30 AU AU2021316723A patent/AU2021316723A1/en active Pending
- 2021-07-30 US US18/002,591 patent/US20230227555A1/en active Pending
- 2021-07-30 EP EP21762622.5A patent/EP4188440A2/en active Pending
- 2021-07-30 WO PCT/EP2021/071491 patent/WO2022023566A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022023566A2 (en) | 2022-02-03 |
| US20230227555A1 (en) | 2023-07-20 |
| AU2021316723A1 (en) | 2023-01-19 |
| JP2023535792A (ja) | 2023-08-21 |
| CN116406274B (zh) | 2026-02-17 |
| CA3185105A1 (en) | 2022-02-03 |
| CN116406274A (zh) | 2023-07-07 |
| WO2022023566A3 (en) | 2022-03-10 |
| EP4188440A2 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202012331D0 (en) | Therapeutic antibodies | |
| IL286000A (en) | Asketamine for the treatment of depression | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| GB2614651B (en) | Antibodies | |
| IL299744A (en) | Antibodies to CD-3 for the treatment of the corona virus | |
| IL308393A (en) | Antibodies for the treatment of alpha-synuclein diseases | |
| GB2627309B (en) | Antibodies | |
| IL317231A (en) | Antibodies against BCMA | |
| IL304200A (en) | Combined treatment using anti-fucosyl-gm1 antibody | |
| GB202304512D0 (en) | Antibodies | |
| GB202217924D0 (en) | Antibodies | |
| GB202204159D0 (en) | Antibodies | |
| ZA202108220B (en) | Association of polyclonal antibodies and anti-pd1 or anti-pdl1 antibodies for the treatment of cancer | |
| IL279684A (en) | A method for purifying cysteamine | |
| GB202311497D0 (en) | Therapeutic antibodies | |
| GB202310818D0 (en) | Therapeutic antibodies | |
| IL314314A (en) | Therapeutic antibodies | |
| GB202300904D0 (en) | Therapeutic antibodies | |
| GB202217993D0 (en) | Therapeutic antibodies | |
| GB202209454D0 (en) | Therapeutic antibodies | |
| GB202208544D0 (en) | Therapeutic antibodies | |
| GB202202990D0 (en) | Therapeutic antibodies | |
| GB202202635D0 (en) | Therapeutic antibodies | |
| IL320200A (en) | Antibodies for cancer treatment anti-BSSL | |
| GB202108677D0 (en) | Therapeutic antibodies |